3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neoplasm Metastasis
3
Melanoma
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Virus Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Pain
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Insulin-Like Growth Factor I, Resistance To
1
Humoral Hypercalcemia Of Malignancy
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Epstein-Barr Virus Infections
1
Disease
1
Interventions
Oncolytic Virotherapy
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
glutathione pegylated liposomal doxorubicin
1
Trastuzumab
1
Telemedicine
1
Radiation
1
Plasma Exchange
1
Mycophenolic Acid
1
Interferon-gamma
1
Immunotherapy
1
COVID-19 Vaccines
1
Azathioprine
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Nervous System Diseases
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled